<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01171781</url>
  </required_header>
  <id_info>
    <org_study_id>2009-09-037</org_study_id>
    <nct_id>NCT01171781</nct_id>
  </id_info>
  <brief_title>A Randomized Phase II Study of Concurrent Chemoradiation With Every 3 Week of Cisplatin vs With Weekly Cisplatin in Locally Advanced Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Randomized Phase II Study of Concurrent Chemoradiation With Every 3 Week of Cisplatin vs With Weekly Cisplatin in Locally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <brief_summary>
    <textblock>
      The study try to show the weekly cisplatin based CCRT is not inferior to 3-weekly cisplabe
      based CCRT in terms of 3-yr progression free survival rate in advanced nasopharyngeal
      carcinoma
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival rate at 3 years</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival rate</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Nasophayngeal Carcinoma Between Stage II and IVb</condition>
  <arm_group>
    <arm_group_label>3 weekly CDDP based CCRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>radiation (conventioal or IMRT) with 3 cycles of 3-weekly cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>weekly cisplatin based CCRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>radiation (conventional or IMRT) with 7 cycles of weekly cisplatin therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin (3 weekly)</intervention_name>
    <description>radiation with cisplatin (100mg/m2) on D1,D22,D43 and followed by adjuvant chemotherapy (3 cycles of FP)</description>
    <arm_group_label>3 weekly CDDP based CCRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin (weekly)</intervention_name>
    <description>radiation with 7 cycles of cisplatin (40mg/m2) on D1,8,15,22,29,36,43, and followed by adjuvant chemothrapy (FP X3)</description>
    <arm_group_label>weekly cisplatin based CCRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed nasopharyngeal carcinoma age of 18 years or over stage II ~
             IVb no history of chemotherapy, radiotherapy, or immunotherapy for NPC with measurable
             lesion based on RECIST 1.1 ECOG PS 0 ~2 good organ function (liver, renal,
             hematologic)

        Exclusion Criteria:

          -  active infectious disease requiring antibiotics uncontrolled heart disease pregnancy
             and on feeding state history of other malignancy within 5 years before enrollment,
             except for well treated non-melanomatous skin cancer, in situ cervical cancer, thyroid
             cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Myung-Ju Ahn, M.D, Ph.D.</last_name>
    <phone>822-3410-3438</phone>
    <email>silkahn@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung-Ju Ahn, M.D., Ph.D.</last_name>
      <phone>822-3410-3438</phone>
      <email>silkahn@skku.edu</email>
    </contact>
    <investigator>
      <last_name>Myung-Ju Ahn, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2010</study_first_submitted>
  <study_first_submitted_qc>July 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2010</study_first_posted>
  <last_update_submitted>July 27, 2010</last_update_submitted>
  <last_update_submitted_qc>July 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Myung-Ju Ahn</name_title>
    <organization>Samsung Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

